Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…Abstract Number: 1045 • 2013 ACR/ARHP Annual Meeting
Under Reporting Of Cataracts In Randomised Controlled Trials Investigating The Use Of Systemic Glucocorticoids In Patients With Rheumatoid Arthritis
Background/Purpose: Oral glucocorticoid (GC) therapy is used in more than half of patients with rheumatoid arthritis (RA). Cataracts are a recognised treatment-related side effect of…Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…Abstract Number: 492 • 2013 ACR/ARHP Annual Meeting
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
Background/Purpose: Glucocorticoids (GC) have been a cornerstone of Rheumatoid arthritis (RA)-therapy for the last decades. However, about a third of RA-patients do not respond adequately.…Abstract Number: 103 • 2013 ACR/ARHP Annual Meeting
Proportion Of U.S. Older Adults Meeting Inclusion Criteria For 2010 ACR Recommendations On Glucocorticoid-Induced Osteoporosis
Background/Purpose: Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. Fracture related to GIO increases a patient’s mortality risk and reduces quality of…Abstract Number: 55 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Receptor Modulator Compound A Does Not Induce Leptin In Human Osteoarthritic Synovial Fibroblasts and In Dedifferentiated Chondrocytes
Background/Purpose: Leptin is generally considered detrimental in osteoarthritis (OA) as it can induce IL-8 in synovial fibroblasts (SF) and matrix metalloproteinases in chondrocytes. We recently…Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting
Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate
Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…Abstract Number: 1663 • 2013 ACR/ARHP Annual Meeting
Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
Background/Purpose: Obesity is not only a risk factor for osteoarthritis but also for rheumatoid arthritis (RA). In obese RA patients, disease incidence is higher and…Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
ACR Meeting Abstracts